Granulomatous prostatitis after BCG therapy for urothelial carcinoma
Research type
Research Study
Full title
Granulomatous prostatitis after BCG therapy for urothelial carcinoma of the bladder - Histopathological observations and clinical correlation
IRAS ID
199300
Contact name
Richard Y Ball
Contact email
Sponsor organisation
Norfolk and Norwich University Hospitals NHS Foundation Trust
Clinicaltrials.gov Identifier
199300 154-10-15, NNUH R&D registration number
Duration of Study in the UK
0 years, 5 months, 0 days
Research summary
The development of granulomatous prostatitis (a form of inflammation in the prostate land) after instilling Bacillus Calmette-Guérin (BCG) into the bladder as therapy for early-stage bladder cancer is a well-recognised and common occurrence. It has been observed predominantly in prostate biopsy specimens. What is not as well-documented or understood are the location in which BCG granulomas are distributed and the qualitative information of their histomorphology (such as size and shape) within specific prostatic zones. By reviewing whole sections of prostate glands removed surgically from patients who have undergone removal of the bladder and prostate after BCG treatment for bladder cancer, we aim to study BCG-type granulomatous inflammation in the prostate and identify any potential patterns of inflammation. Our overall goal is to add to the wider understanding of prostatic inflammation and ultimately, perhaps, processes involved in the development of prostate carcinoma (carcinogenesis).
REC name
London - Harrow Research Ethics Committee
REC reference
16/LO/0568
Date of REC Opinion
24 Mar 2016
REC opinion
Favourable Opinion